Bispecific T-cell engagers are used to treat certain types of blood cancers, including acute lymphoblastic leukemia (ALL), multiple myeloma, and non-Hodgkin lymphoma. They also have other uses in treating various cancers. These medications work by connecting your T-cells, a type of immune cell, to cancer cells, helping your immune system attack and destroy the cancer. Bispecific T-cell engagers are typically given as injections. Examples include Blincyto (blinatumomab), Columvi (glofitamab), and Talvey (teclistamab). These treatments can help target and fight cancer cells more effectively.
